(Reuters) – GlaxoSmithKline Plc said on Thursday its shingles vaccine had been approved for use in China in adults aged 50 and above.
Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds in the latest quarter.
The company said the vaccine will be introduced in phases, starting in 2020 to ensure reliable supply to all countries, where it has been launched.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.